<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104030">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01684761</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol Number 2012-00</org_study_id>
    <nct_id>NCT01684761</nct_id>
  </id_info>
  <brief_title>Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis</brief_title>
  <acronym>Abili-T</acronym>
  <official_title>A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Opexa Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Opexa Therapeutics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Tcelna (imilecleucel-T, autologous T-Cell
      Immunotherapy) is effective in the treatment of secondary progressive multiple sclerosis
      (SPMS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects whose myelin reactive T-cell can be identified by EPA will are  randomized and
      provide blood to manufacture Tcelna.  Approximately 5 weeks after receipt of the subject's
      whole blood procurement, the subjects will receive either Tcelna or placebo and will
      complete baseline assessments and will receive study treatments at Weeks 0, 4, 8, 12, and 24
      (Visits 3-7), totaling 5 doses in year one.

      Approximately one month prior to the Week 52 visit a second blood procurement will be
      performed and the subject will receive the second series of treatments as received in the
      first year study schedule.  Subjects will be evaluated for changes in disability and
      cognitive function every 3 months, and radiographic changes annually.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Brain Atrophy</measure>
    <time_frame>2 Years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The percentage of brain volume change (atrophy) as measured on 24 month MRIs calculated by the central MRI facility.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Progression</measure>
    <time_frame>2 Years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The percentage of subjects with sustained progression with definitions of sustained effect at 3 months and 6 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Autoimmune Diseases of the Nervous System</condition>
  <condition>Multiple Sclerosis</condition>
  <condition>Secondary Progressive Multiple Sclerosis</condition>
  <condition>Disease Progression</condition>
  <condition>Brain Atrophy</condition>
  <arm_group>
    <arm_group_label>Tcelna</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30-45 x 10E6 total cells in 2 ml.  Subjects receive two annual courses of 5 subcutaneous doses each year (at 0, 4, 8, 12 and 24 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tcelna inactive ingredients (without cells) totaling 2 ml per dose.  Administered subcutaneously with same two year treatment regimen as experimental treatment arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tcelna</intervention_name>
    <description>Autologous pool of myelin reactive T-cells (MRTC) expanded ex vivo with immunodominant epitopes selected from the three myelin antigens, MBP, PLP and MOG on a per subject basis.  Attenuated by irradiation to prevent further proliferation before releasing product for administration.</description>
    <arm_group_label>Tcelna</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 ml of Tcelna excipients, prepared daily as individual doses and irradiated before releasing product for administration.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with MS as defined by the modified McDonald criteria

          -  SPMS defined as relapsing-remitting disease with recent progression in MS-related
             neurological deficits

          -  EDSS score 3.0 - 6.0, inclusively

          -  Presence of myelin reactive T-cells

        Exclusion Criteria:

          -  Diagnosed with primary progressive MS

          -  Treatment with beta-interferon, glatiramer acetate or dimethyl fumarate 30 days prior
             to screening

          -  Treatment with ACTH, any over-the-counter or prescription corticosteroids 60 days
             prior to screening

          -  Treatment with IVIG, plasmapheresis or cytopheresis 90 days prior to screening

          -  Treatment with mitoxantrone, teriflunomide, fingolimod, natalizumab, azathioprine,
             cyclosporine, methotrexate or mycophenolate mofetil 1 year prior to baseline

          -  Any prior treatment with cladribine, cyclophosphamide, total lymphoid irradiation, T
             cell or T cell receptor products, or any therapeutic monoclonal antibody, except
             natalizumab

          -  Previous treatment with any other MS investigational drug 1 year prior to screening

          -  All non-MS investigational drugs must have a minimum washout of 30 days prior to
             screening or 5 half-lives, whatever is the longest period of time.

          -  HIV or hepatitis infection

          -  History of cancer

          -  Any other significant medical condition that, in the opinion of the investigator,
             could cause CNS tissue damage or limit its repair.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenny Frazier</last_name>
    <role>Study Director</role>
    <affiliation>Opexa Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HOPE Research Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85050</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maya Hernandez</last_name>
      <phone>602-288-4673</phone>
      <email>maya.hernandez@trialtrack.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Gitt, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest NeuroSpecialists, LLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abrie Schroeder</last_name>
      <phone>520-742-1833</phone>
      <phone_ext>204</phone_ext>
      <email>khale@neuroresearch.com</email>
    </contact>
    <investigator>
      <last_name>Jeanette Wendt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alta Bates Summit Medical Center, The Research and Education Development Institute</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethany Wexler</last_name>
      <phone>510-204-1608</phone>
      <email>wexlerb@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Joanna Cooper, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology Associates, P.A.</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerri Olson</last_name>
      <phone>407-647-5996</phone>
      <phone_ext>241</phone_ext>
    </contact>
    <investigator>
      <last_name>William Honeycutt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanet Babcock</last_name>
      <phone>305-243-1088</phone>
      <email>YBabcock@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>William Sheremata, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Collier Neurologic Specialists, LLC</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Lennertz</last_name>
      <phone>239-434-0332</phone>
      <email>clennertz@collierneurologic.com</email>
    </contact>
    <investigator>
      <last_name>Matthew Baker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurological Services of Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Parrish</last_name>
      <phone>407-240-1762</phone>
      <email>drskochparrish@cfl.rr.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Jacobs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Duncan</last_name>
      <phone>813-877-8839</phone>
    </contact>
    <investigator>
      <last_name>Cynthia Huffman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vero Beach Neurology</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Bussey</last_name>
      <phone>772-569-7039</phone>
      <phone_ext>125</phone_ext>
      <email>vbussey@geodysseyrsch.com</email>
    </contact>
    <investigator>
      <last_name>Stuart Shafer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shepherd Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlyn Kappy</last_name>
      <phone>404-367-1375</phone>
      <email>carlyn_kappy@shepherd.org</email>
    </contact>
    <investigator>
      <last_name>Ben Thrower, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Consultants In Neurology, Ltd.</name>
      <address>
        <city>Northbrook</city>
        <state>Illinois</state>
        <zip>60062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Corsino, RN</last_name>
      <phone>847-509-0270</phone>
      <email>research2@cinltd.com</email>
    </contact>
    <investigator>
      <last_name>Daniel R. Wynn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Neurological Center</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicki Gerbers</last_name>
      <phone>260-436-3991</phone>
      <phone_ext>2143</phone_ext>
    </contact>
    <investigator>
      <last_name>James Stevens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Josephson Wallack Munshower Neurology, PC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy Root</last_name>
      <phone>317-537-6088</phone>
      <phone_ext>1250</phone_ext>
      <email>troot@jwmneuro.com</email>
    </contact>
    <investigator>
      <last_name>Craig Herrman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Schmidt</last_name>
      <phone>913-588-3968</phone>
      <email>lschmidt@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Sharon Lynch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associates in Neurology</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Sanders, BS, CCRC</last_name>
      <phone>859-685-0675</phone>
      <email>laurasanders@ainlex.com</email>
    </contact>
    <investigator>
      <last_name>Cary Twyman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Elizabeth's Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marissa Hone</last_name>
      <phone>617-789-3171</phone>
      <email>marissa.hone@steward.org</email>
    </contact>
    <investigator>
      <last_name>Joshua Katz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Island Neurological Assoicates, PC</name>
      <address>
        <city>Plainview</city>
        <state>New York</state>
        <zip>11803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Harding</last_name>
      <phone>516-822-2230</phone>
      <email>tiffanyharding@aol.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Newman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital and Medical Center Stony Brook New York</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-8121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Traci Brower</last_name>
      <phone>631-444-7210</phone>
      <email>Traci.Brower@stonybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Patricia Coyle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center Neurology</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bridget Loven</last_name>
      <phone>704-446-1987</phone>
      <email>bridget.loven@carolinashealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Jill Conway, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Neurological Institute, PA</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myrna Shrum</last_name>
      <phone>704-372-3714</phone>
      <phone_ext>129</phone_ext>
    </contact>
    <investigator>
      <last_name>T. Hemanth Rao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PMG Research of Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Norton</last_name>
      <phone>704-527-6672</phone>
    </contact>
    <investigator>
      <last_name>Thor Borresen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology Specialists, Inc</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45408</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara Baker, CCRC</last_name>
      <phone>937-495-0000</phone>
      <phone_ext>141</phone_ext>
      <email>Kara.Baker@nsohio.com</email>
    </contact>
    <investigator>
      <last_name>Lawrence Goldstick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Medical Group - Medford</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kari Jaasko</last_name>
      <phone>541-732-8457</phone>
      <email>Kari.Jaasko@providence.org</email>
    </contact>
    <investigator>
      <last_name>Walter Carlini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence St. Vincent Medical Center - Northwest MS Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Turner</last_name>
      <phone>503-216-1017</phone>
      <email>Crystal.Turner2@providence.org</email>
    </contact>
    <investigator>
      <last_name>Stanley Cohan, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Zimmerman</last_name>
      <phone>215-349-5162</phone>
      <email>vanessa.zimmerman@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Clyde Markowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Maxine Mesinger MS Clinic/Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tahari R Griffin, BS, MA</last_name>
      <phone>713-798-8170</phone>
      <email>tgriffin@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>George J Hutton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Texas Neurology</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Mayer</last_name>
      <phone>512-218-1222</phone>
      <email>lori.mayer.msn@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Edward J Fox, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integra Clinical Research, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mechelle Sauvage</last_name>
      <phone>210-853-3952</phone>
      <email>msauvage@integraclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Suzanne Gazda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care - Neurology Service</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Krusinski</last_name>
      <phone>802-847-4256</phone>
      <email>patricia.krusinski@vtmednet.org</email>
    </contact>
    <investigator>
      <last_name>Angela M Applebee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hampton Roads Neurology</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl White</last_name>
      <phone>757-534-5374</phone>
      <email>cheryl.white@rivhs.com</email>
    </contact>
    <investigator>
      <last_name>K. Alvin Lloyd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurological Associates, Inc</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwen Darby</last_name>
      <phone>804-288-1972</phone>
    </contact>
    <investigator>
      <last_name>Alan Schulman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Neuroscience Institute</name>
      <address>
        <city>Issaquah</city>
        <state>Washington</state>
        <zip>98029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuriko Courtney</last_name>
      <phone>206-320-2647</phone>
      <email>Yuriko.Courtney@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Lily Jung Henson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Neuroscience Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuriko Courtney</last_name>
      <phone>206-320-2647</phone>
      <email>Yuriko.Courtney@swedish.org</email>
    </contact>
    <investigator>
      <last_name>James Bowen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lily Jung-Henson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ottawa</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjorie Bowman</last_name>
      <phone>(613) 737-8104</phone>
      <phone_ext>7</phone_ext>
      <email>mbowman@Ottawahospital.on.ca</email>
    </contact>
    <investigator>
      <last_name>Mark Freedman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Recherche Sepmus Inc.</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2J2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute and Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jad Al-Shami</last_name>
      <phone>(514) 398-5750</phone>
      <email>jad.al-shami@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Amit Bar-Or, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.nationalmssociety.org</url>
    <description>Click here for more information about MS and current research.</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 21, 2014</lastchanged_date>
  <firstreceived_date>September 11, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multicenter Study</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Individualized Medicine</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Myelin Proteins</keyword>
  <keyword>Biological Agents</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Autoimmune Diseases</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Autoimmune Diseases of the Nervous System</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
